...
首页> 外文期刊>Blood cancer journal. >Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome
【24h】

Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome

机译:原发性骨髓增生异常综合征患者疾病进展过程中 ASXL1 突变及其他相关遗传变化的动态

获取原文
           

摘要

Recently, mutations of the additional sex comb-like 1 ( ASXL1 ) gene were identified in patients with myelodysplastic syndrome (MDS), but the interaction of this mutation with other genetic alterations and its dynamic changes during disease progression remain to be determined. In this study, ASXL1 mutations were identified in 106 (22.7%) of the 466 patients with primary MDS based on the French-American-British (FAB) classification and 62 (17.1%) of the 362 patients based on the World Health Organization (WHO) classification. ASXL1 mutation was closely associated with trisomy 8 and mutations of RUNX1 , EZH2 , IDH , NRAS , JAK2 , SETBP1 and SRSF2, but was negatively associated with SF3B1 mutation. Most ASXL1- mutated patients (85%) had concurrent other gene mutations at diagnosis. ASXL1 mutation was an independent poor prognostic factor for survival. Sequential studies showed that the original ASXL1 mutation remained unchanged at disease progression in all 32 ASXL1- mutated patients but were frequently accompanied with acquisition of mutations of other genes, including RUNX1 , NRAS, KRAS, SF3B1 , SETBP1 and chromosomal evolution. On the other side, among the 80 ASXL1- wild patients, only one acquired ASXL1 mutation at leukemia transformation. In conclusion, ASXL1 mutations in association with other genetic alterations may have a role in the development of MDS but contribute little to disease progression.
机译:最近,在骨髓增生异常综合征(MDS)患者中发现了其他性梳样1(ASXL1)基因突变,但该突变与其他遗传变异的相互作用及其在疾病进展过程中的动态变化仍有待确定。在这项研究中,根据法国-美国-英国(FAB)分类,在466例原发性MDS患者中,有106例(22.7%)被鉴定为ASXL1突变,根据世界卫生组织(362),在362例患者中,有62例(17.1%)被鉴定为( WHO)分类。 ASXL1突变与三体性8和RUNX1,EZH2,IDH,NRAS,JAK2,SETBP1和SRSF2的突变密切相关,但与SF3B1突变负相关。大多数ASXL1突变的患者(85%)在诊断时同时存在其他基因突变。 ASXL1突变是生存的独立不良预后因素。序列研究表明,在所有32名ASXL1突变的患者中,原始ASXL1突变在疾病进展时均保持不变,但经常伴随着其他基因的突变,包括RUNX1,NRAS,KRAS,SF3B1,SETBP1和染色体进化。另一方面,在80例ASXL1野生患者中,只有一个在白血病转化时获得了ASXL1突变。总之,ASXL1突变与其他基因改变有关,可能在MDS的发生中起作用,但对疾病进展的贡献很小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号